Flemming L. Søndergaard

Author

Novo Nordisk (Denmark)

Also Known As

F Søndergaard, F. L. Søndergaard, F. Søndergaard, Flemming L. Søndergaard, Flemming Søndergaard

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Novo Nordisk (Denmark)Aarhus University Hospital Aarhus University

About

Flemming L. Søndergaard is an author at Novo Nordisk (Denmark) specializing in diabetes, medicine, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	104
2	Diabetes	3	3	104
3	Public Health	2	2	78
4	Pharmacology	2	2	79
5	Health Policy	1	1	25

Flemming L. Søndergaard

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist Stephen T. Buckley, Tine A. Bækdal, Andreas Vegge, Science Translational Medicine	2018	472
Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006 Deirdre Cronin‐Fenton, Flemming L. Søndergaard, Lars Pedersen, British Journal of Cancer	2010	368
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes Charlotte Granhall, Morten Donsmark, Thalia Marie Blicher, Clinical Pharmacokinetics	2018	160
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment Charlotte Granhall, Flemming L. Søndergaard, Mette S. Thomsen, Clinical Pharmacokinetics	2018	113
Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes Torben Biester, Sarah Blaesig, K Remus, Pediatric Diabetes Insulin DegludecUltra-long Pharmacokinetic PropertiesObesityMetabolic SyndromeType 1	2014	53
Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population‐based follow‐up study Henriette Thisted Horsdal, Søren Paaske Johnsen, Flemming L. Søndergaard, Diabetes/Metabolism Research and Reviews	2009	40
Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study Tine A. Bækdal, Morten Donsmark, Marie‐Louise Hartoft‐Nielsen, Clinical Pharmacology in Drug Development	2021	38
Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation Tine A. Bækdal, Astrid Breitschaft, Morten Donsmark, Diabetes Therapy	2021	37
Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus Stefan Korsatko, Sigrid Deller, Julia K. Mader, Drugs & Aging	2013	36
Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case–control study Henriette Thisted Horsdal, Flemming L. Søndergaard, Søren Paaske Johnsen, Pharmacoepidemiology and Drug Safety	2011	27

Page 1